Sertac Vurgun

Dr. Sertac Vurgun

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
GKGul Sema Yildiran Keskin
Gul Sema Yildiran Keskin
ÖYÖzge Yetginoğlu
Özge Yetginoğlu
SVSertac Vurgun
Sertac Vurgun
EGEvrican Zin Guzel
Evrican Zin Guzel
FÖFARİZ EMRAH ÖZKAN
FARİZ EMRAH ÖZKAN
NKNuri Karadurmus
Nuri Karadurmus
Background/Objectives: Metastatic testicular germ cell tumor (mGCT) is a highly curable disease with first-line cisplatin-based combination chemotherapy. This study aims to evaluate the clinicopathological characteristics and survival outcomes of patients with metastatic testicular cancer in a nationwide multicenter cohort. Methods: This multicenter retrospective cohort study included 316 male patients diagnosed with mGCT who were treated with first-line cisplatin-based chemotherapy across 10 institutions in Turkey between 2011 and 2024. Clinical and pathological data, including International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, treatment details, and survival outcomes, were analyzed. Results: The median age of the cohort was 28 years, and 76.3% of patients were diagnosed with non-seminoma. According to IGCCCG risk stratification, 53.2% had good-risk, 25.3% intermediate-risk, and 21.5% poor-risk disease. Median follow-up was 38.4 months. Among patients with seminoma, the 5-year overall survival (OS) rate was 100% in the good-risk group and 87.5% in the intermediate-risk group. In patients with non-seminoma, 5-year OS rates were 96.6%, 86.9%, and 65.1% in the good-, intermediate-, and poor-risk groups, respectively. Among 125 patients who received salvage treatment, high-dose chemotherapy (HDCT) significantly improved survival in the International Prognostic Factors Study Group (IPFSG) very high-risk group (3-year OS: 55.0% vs. 16.3% with conventional-dose chemotherapy (CDCT), p = 0.007). Conclusions: This study provides the first large-scale nationwide dataset on mGCT outcomes in Turkey, demonstrating overall survival rates comparable to international cohorts. The findings emphasize the importance of a multidisciplinary approach, adherence to treatment guidelines, and optimal surgical interventions in improving patient outcomes.

15 August 2026 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
FOFatih Ozbay
Fatih Ozbay
MHMehmet Hünür
Mehmet Hünür
SVSertac Vurgun
Sertac Vurgun
ADAyşe Tan Doğruel
Ayşe Tan Doğruel
GKGülhan Özçelik Köker
Gülhan Özçelik Köker
MKMustafa Karaca
Mustafa Karaca
Aims: Male breast cancer (MBC) is a rare disease, and treatment approaches are largely extrapolated from female breast cancer. This study aims to evaluate clinicopathological features, immunohistochemistry-based surrogate subtypes, treatment approaches, and survival outcomes in MBC patients from Turkiye, where data on this rare disease remain limited. Methods: Forty-seven MBC patients diagnosed between 2005-2024 were retrospectively analyzed. Demographic characteristics, tumor features, immunohistochemistry-based surrogate subtypes, treatment modalities, and survival data were evaluated. Survival analyses were performed using the Kaplan-Meier method, and group comparisons were conducted using the log-rank test. Exploratory associations with overall survival (OS) were evaluated using univariate Cox regression analysis. Analyses used available cases without imputation. Surrogate subtypes were derived from ER, PR, HER2 and Ki-67; HR-positive/HER2negative tumours without Ki-67 were not assigned to luminal A-like or luminal B-like/HER2-negative categories. Results: The median age was 58.4 years (range 31–90), and the median follow-up was 54.9 months (range 2.8–197.3). Stage II was the most common presentation (59.5%), and stage III–IV disease was present in 28.6%. ER/PR/HER2 data were available for 44 patients. Complete five-category immunohistochemistry-based surrogate subtype classification was possible in 35 patients: luminal A-like 31.4% (11/35), luminal B-like/HER2-negative 42.9% (15/35), luminal B-like/HER2-positive 17.1% (6/35), HER2 positive/non-luminal 5.7% (2/35), and triple-negative 2.9% (1/35). Nine additional HR-positive/HER2-negative tumours could not be divided into the two HER2-negative luminal categories because Ki-67 was unavailable. ER positivity was 93.2%, PR positivity 86.4%, and HER2 positivity 18.2%. OS was evaluable in 46 patients; the median OS was 194.3 months and the median disease-free survival was 155.8 months. In exploratory univariate Cox analysis, older age (per 10-year increase: HR 1.76, 95% CI 1.03–2.98, p=0.037), grade 3 histology (HR 3.35, 95% CI 1.17–9.59, p=0.024) and a high Ki-67 index (≥20% vs

30 September 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
FOFatih Ozbay
Fatih Ozbay
MHMehmet Hunur
Mehmet Hunur
SVSertac Vurgun
Sertac Vurgun
SASuleyman Alkan
Suleyman Alkan
SGSema Sezgin Goksu
Sema Sezgin Goksu
MKMustafa Karaca
Mustafa Karaca
Background: We developed clinical–laboratory models for early progression or death within 90 days (EPD90) during PD-1/PD-L1 blockade in advanced non-small cell lung cancer. EPD90 is a pragmatic early-risk endpoint, not a diagnosis of hyperprogressive disease. Methods: This retrospective single-centre cohort included patients treated between January 2018 and March 2026. The four-item baseline score, EPS-4, combined bone metastasis, lactate dehydrogenase (LDH), albumin and C-reactive protein. Among patients alive and progression-free at day 42, D1 added six-week changes in neutrophil-to-lymphocyte ratio (NLR), and D2 additionally included LDH changes. Internal validation used bootstrap resampling and repeated cross-validation. Results: Among 282 patients, 83 (29.4%) had EPD90. In the common baseline complete-case set (n = 252; 76 events), EPS-4 had an apparent area under the curve (AUC) of 0.729 (95% confidence interval [CI] 0.665–0.793). In 238 landmark-eligible complete cases (56 subsequent events), adding NLR change increased AUC from 0.718 to 0.801. Adding LDH yielded an AUC of 0.816, a modest, statistically non-significant increment (delta AUC 0.016; p = 0.094). Bootstrap-corrected calibration slopes were 0.980 for D1 and 0.957 for D2. Conclusions: NLR provided the principal dynamic contribution. D1 is emphasized as the main dynamic model; D2 remains an exploratory extension with uncertain incremental value. Unavailable laboratory collection dates and lack of external validation limit interpretation. The models and proposed thresholds require independent validation before clinical use.

27 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Open access
FOFatih Ozbay
Fatih Ozbay
SVSertac Vurgun
Sertac Vurgun
SASüleyman Alkan
Süleyman Alkan
MKMustafa Karaca
Mustafa Karaca
Amaç: Neoadjuvan kemoterapi (NAKT) uygulanan evre II–III invaziv meme kanserinde HER2-low alt tiplerinin patolojik tam yanıt (pCR) ve sağkalım sonlanımları ile ilişkisini değerlendirmek ve progresyonun bağımsız belirleyicilerini incelemek.Gereç ve Yöntemler: Akdeniz Üniversitesi Tıp Fakültesi’nde 2016-2024 yılları arasında NAKT alıp küratif cerrahi uygulanan 227 ardışık hasta retrospektif olarak analiz edildi. Demografik ve klinikopatolojik özellikler ile ER, PR, Ki-67, HER2 durumu, lenfovasküler invazyon (LVI) ve perinöral invazyon kaydedildi. Patolojik tam yanıt ( pCR ) ve Miller-Payne skoru ile; radyolojik yanıt standart kriterlere göre değerlendirildi. Sağkalım Kaplan-Meier yöntemiyle analiz edildi, gruplar log-rank testi ile karşılaştırıldı. Progresyonun bağımsız belirleyicileri çok değişkenli Cox regresyon analizi ile araştırıldı. HER2-low kavramının HER2-negatif spektrumda yorumlanması gereği dikkate alınarak, HER2-pozitif olgular dışlandıktan sonra HER2-low ve HER2-0 arasında duyarlılık analizi yapıldı.Bulgular: Ortalama yaş 50,1 yıl idi. HER2-low oranı %32,2 (%95 GA: %26,4–%38,5) ve pCR oranı %40,5 (%95 GA: %34,4–%47,0) olarak saptandı. Medyan takip süresi 43,5 ayda 5 yıllık OS %96,1 ve 5 yıllık PFS %86,6 idi. Ana analizde HER2-low ve HER2-0 grupları arasında pCR, OS ve PFS açısından anlamlı fark izlenmedi (tüm p>0,05). Çok değişkenli analizde PR pozitifliği PFS için bağımsız koruyucu faktör (HR 0,31; %95 GA 0,12–0,83), LVI varlığı bağımsız risk faktörü (HR 4,02; %95 GA 1,15–13,96) ve pCR elde edilmesi bağımsız koruyucu faktör (HR 0,20; %95 GA 0,04–0,89) olarak belirlendi. Duyarlılık analizinde de HER2-low ile HER2-0 arasında anlamlı fark gözlenmedi.Sonuç: HER2-low fenotipi tek başına pCR ve sağkalım sonuçlarını belirgin biçimde ayrıştırmazken, PR durumu, LVI ve pCR progresyon riskini daha güçlü ve bağımsız biçimde öngörmektedir.

24 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
FOFatih Ozbay
Fatih Ozbay
MHMehmet Hunur
Mehmet Hunur
SVSertac Vurgun
Sertac Vurgun
SASuleyman Alkan
Suleyman Alkan
SGSema Sezgin Goksu
Sema Sezgin Goksu
MKMustafa Karaca
Mustafa Karaca
Background: Tumour-growth kinetics required to diagnose hyperprogressive disease are often unavailable in routine care. We developed baseline and dynamic clinical–laboratory models for progression or death within 90 days (EPD90), a pragmatic endpoint for early clinical deterioration, and assessed whether six-week laboratory change improved risk estimation. Methods: This retrospective single-centre cohort included consecutive adults with advanced or unresectable non-small cell lung cancer treated with PD-1/PD-L1 blockade between January 2018 and March 2026. EPS-4 combined bone metastasis, lactate dehydrogenase (LDH) >240 U/L, albumin < 3.5 g/dL and C-reactive protein >10 mg/L. Day-42 landmark models added log2 ratios of neutrophil-to-lymphocyte ratio (NLR) and LDH. Performance was assessed with 2000 bootstrap resamples and repeated cross-validation. Results: Among 282 assessable patients, 83 (29.4%) had EPD90. In common complete cases (n = 252; 76 events), EPS-4 had an AUC of 0.729 (95% CI 0.665–0.793). Among 238 patients alive and progression-free at day 42 (56 subsequent events), AUC increased from 0.718 for EPS-4 alone to 0.801 after adding NLR change and 0.816 after adding LDH change. The final increment from LDH was modest (ΔAUC 0.016; P = 0.094). Conclusions: Baseline EPS-4 and early NLR change identified higher-risk patients, but the models remain development-stage and require independent prospective validation.